Why SELL?
See Bull/Bear case, catalysts, and full risk analysis
See why ($2.99)
Money back if you are not satisfied
Summary
1.
Sentiment has weakened: relief from a smaller-than-expected loss is outweighed by dilution (ATM) concerns and continued negative free cash flow/high leverage despite the refinancing.
2.
Trots en återhämtning i biobesök är bolagets fundamentala situation med en skuld på 8,2 miljarder USD och ständiga utspädningar extremt ogynnsam för långsiktiga investerare.
3.
Bull case: - **Meme-stock momentum** kan återkomma vid hög blankning
- **Starka filmpremiärer** (t.ex. Avatar 3) kan driva kortsiktigt kassaflöde
- **Rekordbesök** under storhelger visar på fortsatt efterfrågan
Latest news
Since 2026-02-16: (1) Q4 2025 earnings (Feb 24): net loss $127.4M (improved YoY), revenue about $1.29B and attendance down ~10% to 56.3M; management highlighted a stronger 2026 film slate. (2) Refinancing (Feb 23): offering of roughly $1.73B secured notes due 2031 to redeem/refinance nearer-term maturities (incl. 2027-related debt), extending the maturity runway. (3) Dilution (Feb 20): ~20.4M Class A shares sold via ATM for ~$26.2M gross; ongoing concern about further ATM capacity up to $150M.